Free tool
FAERS Monitor: Xerese
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022436 or its brand name (Xerese, Acyclovir, Hydrocortisone). Reports on generic versions are filed under their own applications.
Reports
40
Serious
24
60% of reports
Hospitalization
5
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pain11
- inflammation9
- oedema peripheral9
- pharyngeal paraesthesia9
- off label use4
- drug ineffective3
- herpes zoster3
- pain in extremity3
- application site pain2
- arthropathy2
- malaise2
- myocardial infarction2
- paraesthesia2
- rash2
- abdominal pain1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 11 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,119 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pharyngeal paraesthesiaSignal | 9 | 3000.1 | 1684.4 | 23,933 |
| inflammationSignal | 9 | 91.7 | 51.6 | 721 |
| application site pain | 2 | 47.7 | 12.4 | 51 |
| oedema peripheralSignal | 9 | 38.8 | 21.8 | 297 |
| herpes zosterSignal | 3 | 27.5 | 9.2 | 52 |
| arthropathy | 2 | 18.9 | 4.9 | 18 |
| painSignal | 11 | 9.4 | 5.7 | 77 |
| paraesthesia | 2 | 6.7 | 1.7 | 5 |
| myocardial infarction | 2 | 6.0 | 1.6 | 4 |
| pain in extremitySignal | 3 | 5.4 | 1.8 | 7 |
| rash | 2 | 2.4 | 0.6 | 1 |
| off label use | 4 | 2.4 | 0.9 | 2 |
| malaise | 2 | 2.4 | 0.6 | 1 |
| abdominal pain | 1 | 2.3 | 0.3 | 0 |
| drug ineffective | 3 | 1.2 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.